Tempus Extends AstraZeneca Services Pact With $200 Million Five-Year Commitment
AstraZeneca committed to $200 million in fees to Tempus during a renewed five-year term, according to an 8-K filing.
AstraZeneca committed to $200 million in fees to Tempus during a renewed five-year term, according to an 8-K filing.